Vyondys 53 generics — when can they launch?
Vyondys 53 (GOLODIRSEN) · Sarepta · 1 active US patent · 0 expired
Where Vyondys 53 sits in the generic timeline
Imminent generic cliff: earliest active US patent for Vyondys 53 expires in 2028 (~2 years from today). ANDA filers are likely already preparing Paragraph IV certifications. Expect first-filer 180-day exclusivity competition imminently.
Under US Hatch-Waxman, a generic enters via an ANDA (Abbreviated New Drug Application) and may file with one of four Paragraph IV certifications attacking the brand's listed patents. If the brand sues within 45 days, a 30-month FDA approval stay is triggered. First Para IV filer typically gets 180-day market exclusivity.
Patent estate by type — active patents
Method-of-use patents only carve out specific indications; generics can launch with a "skinny label" omitting those uses. Composition-of-matter patents block the molecule itself.
- Formulation — 1 patent
Sample patent estate
Showing 1 of 1 active US patents. View full estate on the Vyondys 53 drug page →
-
This patent protects a formulation of the drug product Vyondys 53.
Sources
- FDA Orange Book — patents listed against Vyondys 53 (NDA filed 2019)
- Vyondys 53 drug profile — full patent estate, indications, clinical trials, pricing
- Sarepta patent portfolio
- Patent cliff 2028 — every drug losing US exclusivity that year
Patent term extensions (PTR, pediatric exclusivity), Hatch-Waxman 30-month stays, and FDA regulatory exclusivity (NCE/ODE/PED) may shift the effective generic entry date. Not legal advice.
Get generic entry alerts
Free Pharma CI alerts on Vyondys 53 — get notified the moment an ANDA Paragraph IV certification is filed, a 30-month stay is triggered, or a generic launches. First 2 drugs free.
Subscribe free →